{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:30:19Z","timestamp":1790735419876,"version":"4.1.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Outcomes for patients with unresectable stage III non\u2013small cell lung cancer (NSCLC) treated with chemoradiation therapy (CRT) have improved with adjuvant immune checkpoint inhibitors, with a reported 5-year overall survival benefit of approximately 10% for adjuvant durvalumab vs placebo after completion of CRT without progression and with preserved performance status. Starting atezolizumab prior to CRT may allow more patients to benefit from immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate clinical outcomes of patients treated with atezolizumab before and after CRT for unresectable stage III NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This single-cohort, phase II, nonrandomized controlled trial was conducted at 11 US sites. Patients with pathologically confirmed, unresectable stage III NSCLC who were treatment naive and had good performance status were enrolled between January 3, 2018, and July 24, 2019. Data were locked on March 21, 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>\n                      Patients received four 21-day cycles of atezolizumab, 1200 mg intravenously, with therapy administered on day 1 of each cycle. Patients not experiencing tumor progression continued to CRT (60 Gy to involved fields) concurrent with weekly carboplatin area under the curve of 2 and paclitaxel, 50 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , followed by planned consolidation carboplatin area under the curve of 6 and paclitaxel, 200 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , for two 21-day cycles. Patients not experiencing progression continued atezolizumab, 1200 mg, every 21 days to complete 1 year of therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary end point was the disease control rate at 12 weeks. Secondary end points were progression-free survival, overall survival, overall response rate, safety, and translational science end points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 62 patients (median [range] age, 63.9 [38.1-86.5] years; 32 female [51.6%]) were enrolled and received at least 1 dose of atezolizumab. The disease control rate at 12 weeks was 74.2% (80% CI, 65.7%-81.4%). Median progression-free survival was 30.0 months (95% CI, 15.8 to not evaluable), and the median overall survival was not reached. The overall survival rate at 24 months was 73.7% (95% CI, 63.4%-85.7%), and the overall response rate was 66.2%. Seventeen patients (27.4%) experienced grade 3 or higher immune-related adverse events, including 1 with grade 5 pneumonitis and 1 with grade 4 Guillain-Barr\u00e9 syndrome. Thirty patients (48.4%) experienced grade 3 or higher treatment-related adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>These findings suggest that neoadjuvant atezolizumab merits further study based on safety and encouraging outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03102242\">NCT03102242<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.1897","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T11:40:53Z","timestamp":1721907653000},"page":"1212","source":"Crossref","is-referenced-by-count":58,"title":["Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non\u2013Small Cell Lung Cancer"],"prefix":"10.1001","volume":"10","author":[{"given":"Helen J.","family":"Ross","sequence":"first","affiliation":[{"name":"Rush University Cancer Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kozono","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Partners CancerCare, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei F.","family":"Wang","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center and Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James John","family":"Urbanic","sequence":"additional","affiliation":[{"name":"Radiation Medicine and Applied Sciences, University of California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence M.","family":"Williams","sequence":"additional","affiliation":[{"name":"Radiation Oncology, City of Hope, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth D.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Carbone","sequence":"additional","affiliation":[{"name":"Internal Medicine, Medical Oncology, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjun","family":"Chung","sequence":"additional","affiliation":[{"name":"Internal Medicine, Medical Oncology, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Robb","sequence":"additional","affiliation":[{"name":"Radiation Oncology, University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Yul","family":"Byun","sequence":"additional","affiliation":[{"name":"Internal Medicine, Medical Oncology, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Talabere","sequence":"additional","affiliation":[{"name":"Internal Medicine, Medical Oncology, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carter","family":"DuFrane","sequence":"additional","affiliation":[{"name":"Alliance Foundation Trials, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilze","family":"Bara","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Schulze","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Brockman","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junheng","family":"Gao","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center and Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett E.","family":"Vokes","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Stinchcombe","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"13","key":"coi240025r1","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1200\/JCO.2006.07.3569","article-title":"Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B.","volume":"25","author":"Vokes","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi240025r2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7","key":"coi240025r3","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer.","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"issue":"20","key":"coi240025r4","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer.","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"coi240025r5","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer.","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"20","key":"coi240025r6","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"coi240025r8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"coi240025r11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.copbio.2020.07.010","article-title":"T-cell repertoire analysis and metrics of diversity and clonality.","volume":"65","author":"Chiffelle","year":"2020","journal-title":"Curr Opin Biotechnol"},{"issue":"282","key":"coi240025r12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"coi240025r13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time.","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"issue":"7528","key":"coi240025r14","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance.","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"9","key":"coi240025r15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial.","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol"},{"key":"coi240025r7","volume-title":"AJCC Cancer Staging Manual","author":"American Joint Commission on Cancer","year":"2011","edition":"7th ed"},{"key":"coi240025r9","unstructured":"National Institutes of Health. Amendment: NIH policy and guidelines on the inclusion of women and minorities as subjects in clinical research. Notice No. NOT-OD-18-014. Accessed June 8, 2024. https:\/\/grants.nih.gov\/grants\/guide\/notice-files\/NOT-OD-18-014.html"},{"key":"coi240025r10","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Accessed June 8, 2024. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_40"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2821598\/jamaoncology_ross_2024_oi_240025_1726602719.65222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T12:33:40Z","timestamp":1726749220000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2821598"}},"subtitle":["A Phase II Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.1897","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}